---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029582"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:10:42.716576+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M

## Summary
- Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.
- Workforce reduction of ~30% and cash burn cut ~25% as part of strategic restructuring.
- Q2 net loss $68.9M ($0.62/share); cash $271.5M; expects runway into Q2 2027.
- Clinical hold on RP-A501 Danon disease trial ongoing after patient death; engaging with FDA.
- Chris Stevens appointed COO in July; former Spark Therapeutics executive.

## SEC filing metadata
- accession: 0001140361-25-029582
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/0001140361-25-029582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029582
- JSON: https://secwatch.observer/filing/0001140361-25-029582.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.